2020 BIO Investor Forum Buzz of BIO Finalist
Aurora Oncology is an early clinical stage biopharmaceutical company developing targeted therapeutics to treat bladder cancer. Our technologies are based on the clinical observation that bladder cancer cells, as opposed to healthy uroepithelial cells, overexpress epidermal growth factor receptors (EGFR) on the luminal surface of the bladder, providing a readily accessible target for treatment.
Our lead product is an epidermal growth factor-diphtheria toxin-A fusion protein (DT-EGF) for intravesicular treatment of superficial bladder cancer (also known as non-muscle invasive bladder cancer; NIMBC). DT-EGF is poised to enter clinical development. A 2nd product in an earlier stage of development is comprised of a gold nanorod-anti-EGFR mAb fluorophore conjugate (Nano-anti-EGFR) with potential to detect and treat superficial bladder cancer. A 3rd product is being explored for metastatic BC (AO-201).
Aurora Oncology is an early clinical stage biopharmaceutical company developing targeted therapeutics to treat bladder cancer. Our technologies are based on the clinical observation that bladder cancer cells, as opposed to healthy uroepithelial cells, overexpress epidermal growth factor receptors (EGFR) on the luminal surface of the bladder, providing a readily accessible target for treatment.
Our lead product is an epidermal growth factor-diphtheria toxin-A fusion protein (DT-EGF) for intravesicular treatment of superficial bladder cancer (also known as non-muscle invasive bladder cancer; NIMBC). DT-EGF is poised to enter clinical development. A 2nd product in an earlier stage of development is comprised of a gold nanorod-anti-EGFR mAb fluorophore conjugate (Nano-anti-EGFR) with potential to detect and treat superficial bladder cancer. A 3rd product is being explored for metastatic BC (AO-201).
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Colorado
Company HQ Country:
United States
Year Founded:
2013
Main Therapeutic Focus:
Oncology
Lead Product in Development:
EGF-Diphtheria toxin fusion protein
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
